Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

Emanuel Nicolas (1) , Francois Bertucci (1) , Renaud Sabatier (1) , Anthony Goncalves (2, 1)

1 CRCM - Centre de Recherche en Cancérologie de Marseille
2 Institut Paoli-Calmettes

Breast cancers (BC) associated with germline mutations of BRCA1/2 represent 3-5% of cases. BRCA1/2-associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review, we will summarize clinical trials of chemotherapy and PARP inhibitors (PARPi), alone or in combination, at the early or late stage of BRCA1/2-associated BC. We will also present the mechanisms of resistance to PARPi as well as the new therapeutic strategies of association with PARPi. Finally, we will discuss under which conditions the use of DNA damaging agents can be extended to the BRCA1/2-wild type population, the BRCAness concept.

Domains: Life Sciences [q-bio]

Emanuel Nicolas, Francois Bertucci, Renaud Sabatier, Anthony Goncalves. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers, 2018, 10 (12), ⟨10.3390/cancers10120506⟩. ⟨hal-02143625⟩